Insights

Grant-backed funding Neurexis has secured multiple NIH SBIR grants totaling over four million dollars, demonstrating credible validation of its neuroprotective peptide program and potential for continued funding support. This signals credibility when engaging potential partners or customers in government-funded collaboration discussions.

Early-stage but funded With a small team (2-10 employees) and revenue under one million, Neurexis represents a lean, early-stage opportunity ideal for collaboration, licensing, or milestone-based partnerships rather than full-scale procurement. Partners can propose co-development or sponsored research aligned with NIH-funded programs.

Neuroprotection focus The company specializes in neuroprotective interventions for cerebral ischemia, offering a concrete therapeutic niche that aligns with unmet medical needs in stroke and global cerebral ischemia. Potential customers include academic labs, contract research organizations, and biotech/pharma pursuing CNS neuroprotection pipelines.

Innovation leverage Recent SBIR funding and ongoing preclinical validation in both small and large animal models suggest a compelling R&D trajectory. Engaging with Neurexis early could secure co-development agreements, sponsored studies, or milestone-based licensing as the program advances toward clinical trials.

Strategic partnerships The company’s NIH-backed progress and proximity to translational pipelines position it well for strategic collaboration with larger biotechs or pharma firms seeking asset diversification in neurology, enabling potential exit routes such as licensing deals or joint ventures as funding and data mature.

Similar companies to Neurexis Therapeutics

Neurexis Therapeutics Tech Stack

Neurexis Therapeutics uses 8 technology products and services including Open Graph, RSS, WordPress, and more. Explore Neurexis Therapeutics's tech stack below.

  • Open Graph
    Content Management System
  • RSS
    Content Management System
  • Content Management System
  • E-commerce
  • Font Awesome
    Font Scripts
  • jQuery Migrate
    Javascript Libraries
  • Lodash
    Javascript Libraries

Media & News

Neurexis Therapeutics's Email Address Formats

Neurexis Therapeutics uses at least 1 email format:
Neurexis Therapeutics Email FormatsExamplePercentage
First.Last@neurexistherapeutics.comJohn.Doe@neurexistherapeutics.com
100%

Frequently Asked Questions

What is Neurexis Therapeutics's official website and social media links?

Minus sign iconPlus sign icon
Neurexis Therapeutics's official website is neurexistherapeutics.com and has social profiles on LinkedIn and Crunchbase.

How much revenue does Neurexis Therapeutics generate?

Minus sign iconPlus sign icon
As of November 2026, Neurexis Therapeutics's annual revenue is estimated to be <$1M.

What is Neurexis Therapeutics's SIC code and NAICS code?

Minus sign iconPlus sign icon
Neurexis Therapeutics's SIC code is 8731 - Commercial Physical and Biological Research and NAICS code is 541714 - Research and Development in Biotechnology (except Nanobiotechnology).

How many employees does Neurexis Therapeutics have currently?

Minus sign iconPlus sign icon
As of November 2026, Neurexis Therapeutics has approximately 4 employees across 1 continents, including North America. Key team members include Chief Executive Officer | Chair, Board Of Directors | Co-Founder: M. A., Vice President Of Research And Development: R. G. and Principal: P. H. Explore Neurexis Therapeutics's employee directory with LeadIQ.

What industry does Neurexis Therapeutics belong to?

Minus sign iconPlus sign icon
Neurexis Therapeutics operates in the Biotechnology Research industry.

What technology does Neurexis Therapeutics use?

Minus sign iconPlus sign icon
Neurexis Therapeutics's tech stack includes Open Graph, RSS, WordPress, WooCommerce, Google Workspace, Font Awesome, jQuery Migrate and Lodash.

What is Neurexis Therapeutics's email format?

Minus sign iconPlus sign icon
Neurexis Therapeutics's email format typically follows the pattern of First.Last@neurexistherapeutics.com. Find more Neurexis Therapeutics email formats with LeadIQ.

How much funding has Neurexis Therapeutics raised to date?

Minus sign iconPlus sign icon
As of November 2026, Neurexis Therapeutics has raised $4.2M in funding. The last funding round occurred on Sep 16, 2024 for $3M.
Neurexis Therapeutics logo

Neurexis Therapeutics

Biotechnology ResearchColorado, United States2-10 Employees

Neurexis Therapeutics is a biotechnology research company focused on developing neuroprotective interventions, specifically an optimized peptide demonstrated to be effective and safe in animal models of global cerebral ischemia. Based in Aurora, Colorado, the firm operates within the biotechnology research sector and targets applications that address neurological injury, aiming to advance clinical options for conditions arising from cerebral ischemia. The organization appears to maintain a small operations footprint, with activities centered on preclinical or translational research in neuroprotection, supported by a history of NIH-funded grant programs. A notable recent development is the company’s recognition by the NIH in pursuing later-stage development under the SBIR program, reflecting ongoing work toward clinical advancement in its therapeutic area.

Section iconCompany Overview

SIC Code
8731 - Commercial Physical and Biological Research
NAICS Code
541714 - Research and Development in Biotechnology (except Nanobiotechnology)
Employees
2-10

Section iconFunding & Financials

  • $4.2M

    Neurexis Therapeutics has raised a total of $4.2M of funding over 5 rounds. Their latest funding round was raised on Sep 16, 2024 in the amount of $3M as a Grant.

  • <$1M

    Neurexis Therapeutics's revenue is estimated to be in the range of <$1M

Ready to create more pipeline?

Get a demo and discover why thousands of SDR and Sales teams trust
LeadIQ to help them build pipeline confidently.

© LeadIQ, Inc. All rights reserved.